R. A. Kyle, S. V. Rajkumar, and . Multiple, Blood, vol.111, pp.2962-2972, 2008.

M. Attal, Lenalidomide maintenance after stem-cell transplantation for multiple myeloma, N. Engl. J. Med, vol.366, pp.1782-1791, 2012.
URL : https://hal.archives-ouvertes.fr/hal-00852275

P. L. Mccarthy, Lenalidomide after stem-cell transplantation for multiple myeloma, N. Engl. J. Med, vol.366, pp.1770-1781, 2012.

P. L. Mccarthy, Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis, J. Clin. Oncol, vol.35, pp.3279-3289, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01697539

D. P. Steensma, Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes, Blood, vol.126, pp.9-16, 2015.

M. Xie, Age-related mutations associated with clonal hematopoietic expansion and malignancies, Nat. Med, vol.20, pp.1472-1478, 2014.

G. Genovese, Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence, N. Engl. J. Med, vol.371, pp.2477-2487, 2014.

S. Jaiswal, Age-related clonal hematopoiesis associated with adverse outcomes, N. Engl. J. Med, vol.371, pp.2488-2498, 2014.

D. P. Steensma, Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes, Blood, vol.126, pp.9-16, 2015.

C. J. Gibson and D. P. Steensma, New insights from studies of clonal hematopoiesis, Clin. Cancer Res, vol.24, pp.4633-4642, 2018.

S. Jaiswal, Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease, N. Engl. J. Med, vol.377, pp.111-121, 2017.

F. Zink, Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly, Blood, vol.130, pp.742-752, 2017.

A. L. Young, G. A. Challen, B. M. Birmann, and T. E. Druley, Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults, Nat. Commun, vol.7, p.12484, 2016.

S. Abelson, Prediction of acute myeloid leukaemia risk in healthy individuals, Nature, vol.559, pp.400-404, 2018.

P. Desai, Somatic mutations precede acute myeloid leukemia years before diagnosis, Nat. Med, vol.24, pp.1015-1023, 2018.

A. L. Young, R. S. Tong, B. M. Birmann, and T. E. Druley, Clonal hematopoiesis and risk of acute myeloid leukemia, Haematologica, vol.104, pp.2410-2417, 2019.

T. N. Wong, Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia, Nature, vol.518, pp.552-555, 2015.

C. C. Coombs, Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes, Cell Stem Cell, vol.21, p.4, 2017.

C. J. Gibson, Clonal hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma, J. Clin. Oncol, vol.35, pp.1598-1605, 2017.

K. Takahashi, Preleukaemic clonal haemopoiesis and risk of therapyrelated myeloid neoplasms: a case-control study, Lancet Oncol, vol.18, pp.100-111, 2017.

N. K. Gillis, Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study, Lancet Oncol, vol.18, pp.112-121, 2017.

S. Chitre, Clonal hematopoiesis in patients with multiple myeloma undergoing autologous stem cell transplantation, Leukemia, vol.32, pp.2020-2024, 2018.

B. A. Walker, Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma, Blood, vol.132, pp.587-597, 2018.

B. A. Walker, Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma, J. Clin. Oncol, vol.33, pp.3911-3920, 2015.

N. Bolli, Heterogeneity of genomic evolution and mutational profiles in multiple myeloma, Nat. Commun, vol.5, p.2997, 2014.

F. Maura, Genomic landscape and chronological reconstruction of driver events in multiple myeloma, Nat. Commun, vol.10, p.3835, 2019.
URL : https://hal.archives-ouvertes.fr/inserm-02290176

J. G. Lohr, Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy, Cancer Cell, vol.25, pp.91-101, 2014.

S. Wuilleme, Assessment of tumoral plasma cells in apheresis products for autologous stem cell transplantation in multiple myeloma, Bone Marrow Transplant, vol.51, pp.1143-1145, 2016.

H. G. Kopp, S. Yildirim, K. C. Weisel, L. Kanz, and W. Vogel, Contamination of autologous peripheral blood progenitor cell grafts predicts overall survival after high-dose chemotherapy in multiple myeloma, J. Cancer Res Clin. Oncol, vol.135, pp.637-642, 2009.

J. D. Kahn, PPM1D-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells, Blood, vol.132, pp.1095-1105, 2018.

J. I. Hsu, PPM1D mutations drive clonal hematopoiesis in Rresponse to cytotoxic chemotherapy, Cell Stem Cell, vol.23, pp.700-713, 2018.

S. Boettcher, A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies, Science, vol.365, pp.599-604, 2019.

J. J. Fuster, Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice, Science, vol.355, pp.842-847, 2017.

L. Lode, Emergence and evolution of TP53 mutations are key features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide, Haematologica, vol.103, pp.143-149, 2018.

M. Jadersten, TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression, J. Clin. Oncol, vol.29, pp.1971-1979, 2011.

M. Attal, Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma, N. Engl. J. Med, vol.376, pp.1311-1320, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01557406

E. A. Stadtmauer, Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: results of the BMT CTN 0702 trial, J. Clin. Oncol, vol.37, pp.589-597, 2019.

S. K. Kumar, Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma, Cancer, vol.118, pp.1585-1592, 2012.

N. C. Dunavin, Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma, Leuk. Lymphoma, vol.54, pp.1658-1664, 2013.

F. Gay, Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis, Leukemia, vol.31, pp.1727-1734, 2017.

V. A. Adalsteinsson, Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors, Nat. Commun, vol.8, p.1324, 2017.

G. Ha, Integrative analysis of genome-wide loss of heterozygosity and monoallelic expression at nucleotide resolution reveals disrupted pathways in triple-negative breast cancer, Genome Res, vol.22, 1995.

G. Ha, TITAN: inference of copy number architectures in clonal cell populations from tumor whole-genome sequence data, Genome Res, vol.24, pp.1881-1893, 2014.

M. A. Chapman, Initial genome sequencing and analysis of multiple myeloma, Nature, vol.471, pp.467-472, 2011.

M. A. Depristo, A framework for variation discovery and genotyping using next-generation DNA sequencing data, Nat. Genet, vol.43, pp.491-498, 2011.

K. Cibulskis, Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples, Nat. Biotechnol, vol.31, pp.213-219, 2013.

C. T. Saunders, Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs, Bioinformatics, vol.28, pp.1811-1817, 2012.

M. Costello, Discovery and characterization of artifactual mutations in deep coverage targeted capture sequencing data due to oxidative DNA damage during sample preparation, Nucleic Acids Res, vol.41, p.67, 2013.

M. S. Lawrence, Discovery and saturation analysis of cancer genes across 21 tumour types, Nature, vol.505, pp.495-501, 2014.

S. L. Carter, Absolute quantification of somatic DNA alterations in human cancer, Nat. Biotechnol, vol.30, pp.413-421, 2012.

A. Mckenna, The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data, Genome Res, vol.20, pp.1297-1303, 2010.

W. Mclaren, The Ensembl variant effect predictor, Genome Biol, vol.17, p.122, 2016.

A. H. Ramos, Oncotator: cancer variant annotation tool, Hum. Mutat, vol.36, pp.2423-2429, 2015.

G. Jun, Detecting and estimating contamination of human DNA samples in sequencing and array-based genotype data, Am. J. Hum. Genet, vol.91, pp.839-848, 2012.

K. J. Karczewski, The ExAC browser: displaying reference data information from over 60 000 exomes, Nucleic Acids Res, vol.45, pp.840-845, 2017.

R. C. Lindsley, Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation, N. Engl. J. Med, vol.376, pp.536-547, 2017.

M. Lek, Analysis of protein-coding genetic variation in 60,706 humans, Nature, vol.536, pp.285-291, 2016.

J. T. Robinson, Integrative genomics viewer, Nat. Biotechnol, vol.29, pp.24-26, 2011.

M. D. Stachler, Paired exome analysis of Barrett's esophagus and adenocarcinoma, Nat. Genet, vol.47, pp.1047-1055, 2015.

P. R. Greipp, International staging system for multiple myeloma, J. Clin. Oncol, vol.23, pp.3412-3420, 2005.

T. H. Conceptualization, A. S. , C. J. , S. Manier, B. L. et al., Writing -Original Draft, and I.M.G. Competing interests The authors declare the following competing interests: M.B.: Dava Oncology: Honoraria. N.C.M.: OncoPep: Other: Board of director. K.C.A.: Gilead: Membership on an entity's

. Bristol-myers-squibb-;-consultancy;-millennium, . Takeda, and . P. Consultancy, Oncopeptides: Membership on an entity's Board of Directors or advisory committees; BMS: Research Funding; Janssen: Membership on an entity's Board of Directors or advisory committees; Karyopharm: Membership on an entity's Board of Directors or advisory committees; Jazz Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees, Research

. Equillium, Research Funding

/. Kite and . Gilead, Research Funding

. B. Consultancy, Celgene: Research funding; Deerfield: Research funding; GRAIL: Consultancy; Exo Therapeutics: scientific advisory boards; Skyhawk Therapeutics: scientific advisory boards, Talaris Therapeutics: Consultancy; TScan Therapuetics

P. G. Vor:-consultancy;-novartis:-consultancy, Celgene: Consultancy; Janssen: Consultancy; BMS: Consultancy; Takeda: Consultancy; GSK: Consultancy; Sanofi: Consultancy; Karyopharm: Consultancy; Abbvie: Consultancy; Cellectar: Consultancy; Genentech: Consultancy, receives research funds from IBM and Pharmacyclics and is an inventor on patent applications related to MuTect, ABSOLUTE, MutSig